国海证券给予天坛生物买入评级，公司2024年Q3利润平稳，外延并购再下一城

每日经济新闻10-29

国海证券10月28日发布研报称，给予天坛生物（600161.SH，最新价：21.84元）买入评级。评级理由主要包括：1）公司2024年Q3收入承压、利润平稳；2）公司2024Q3毛利率提升、销售费用率降低，推动净利润率同比提升；3）外延并购再下一城，公司收购武汉中原瑞德。风险提示：产品销售推广不及预期，产品研发进展不及预期，浆站获批进展不及预期，新产能建设进展不及预期，并购整合进展不国海证券研究所...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2479444599?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-29 14:10","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2479444599","market":"sh","top_or_hot":-1,"title":"国海证券给予天坛生物买入评级，公司2024年Q3利润平稳，外延并购再下一城","media":"每日经济新闻","content":"<div>\n<p>国海证券10月28日发布研报称，给予天坛生物（600161.SH，最新价：21.84元）买入评级。评级理由主要包括：1）公司2024年Q3收入承压、利润平稳；2）公司2024Q3毛利率提升、销售费用率降低，推动净利润率同比提升；3）外延并购再下一城，公司收购武汉中原瑞德。风险提示：产品销售推广不及预期，产品研发进展不及预期，浆站获批进展不及预期，新产能建设进展不及预期，并购整合进展不国海证券研究所...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029143011ab7dbe89&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国海证券给予天坛生物买入评级，公司2024年Q3利润平稳，外延并购再下一城</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国海证券给予天坛生物买入评级，公司2024年Q3利润平稳，外延并购再下一城\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-29 14:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029143011ab7dbe89&s=b><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>国海证券10月28日发布研报称，给予天坛生物（600161.SH，最新价：21.84元）买入评级。评级理由主要包括：1）公司2024年Q3收入承压、利润平稳；2）公司2024Q3毛利率提升、销售费用率降低，推动净利润率同比提升；3）外延并购再下一城，公司收购武汉中原瑞德。风险提示：产品销售推广不及预期，产品研发进展不及预期，浆站获批进展不及预期，新产能建设进展不及预期，并购整合进展不国海证券研究所...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029143011ab7dbe89&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600161","symbol_name":"天坛生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029143011ab7dbe89&s=b","article_id":"2479444599","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029143011ab7dbe89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2479444599","pubTimestamp":1730182226,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"国海证券10月28日发布研报称，给予天坛生物买入评级。评级理由主要包括：1）公司2024年Q3收入承压、利润平稳；2）公司2024Q3毛利率提升、销售费用率降低，推动净利润率同比提升；3）外延并购再下一城，公司收购武汉中原瑞德。AI点评：天坛生物近一个月获得4份券商研报关注，买入2家，增持1家。文章来源：每日经济新闻国海证券给予天坛生物买入评级，公司2024年Q3利润平稳，外延并购再下一城","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"600161":"天坛生物","000750":"国海证券"},"translate_title":"Guohai Securities gave Tiantan Biotech a buy rating. The company's Q3 profit in 2024 will be stable, and external mergers and acquisitions will make another success","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600161":1,"000750":1},"content_text":"国海证券10月28日发布研报称，给予天坛生物（600161.SH，最新价：21.84元）买入评级。评级理由主要包括：1）公司2024年Q3收入承压、利润平稳；2）公司2024Q3毛利率提升、销售费用率降低，推动净利润率同比提升；3）外延并购再下一城，公司收购武汉中原瑞德。风险提示：产品销售推广不及预期，产品研发进展不及预期，浆站获批进展不及预期，新产能建设进展不及预期，并购整合进展不国海证券研究所请务必阅读正文后免责条款部分及预期，产品质量风险。AI点评：天坛生物近一个月获得4份券商研报关注，买入2家，增持1家。文章来源：每日经济新闻原标题：国海证券给予天坛生物买入评级，公司2024年Q3利润平稳，外延并购再下一城","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479444599"}